TY - JOUR
T1 - Functionally fused antibodies--a novel adjuvant fusion system
AU - Larsen, Martin
AU - Jensen, Kim Bak
AU - Christensen, Peter Astrup
AU - Suarez, Eduardo
AU - Paris, Dominique
AU - Sanz, Laura
AU - Ravn, Peter
AU - Sauce, Delphine
AU - Saas, Philippe
AU - Goletz, Steffen
AU - Alvarez-Vallina, Luis
AU - Kristensen, Peter
PY - 2008/12/31
Y1 - 2008/12/31
N2 - Antibodies capable of recognizing key molecular targets isolated e.g. by phage display technology have been used in the pursuit of new and improved therapies for prevalent human diseases. These approaches often take advantage of non-immunogenic antibody fragments to achieve specific toxin-, radioactivity- or effector-domain delivery. There is now a growing interest in using anti-idiotypic antibodies or other antigen mimics to induce potent immune responses against antigen structures in question. We have earlier reported on the functional rescue of antibodies that are active when fused to the phage, but inactive as soluble protein [Jensen, K.B., Larsen, M., Pedersen, J.S., Christensen, P.A., Alvarez-Vallina, L., Goletz, S., Clark, B.F. and Kristensen, P. (2002) Functional improvement of antibody fragments using a novel phage coat protein III fusion system. Biochem. Biophys. Res. Commun. 298, 566-73.]. The rescue was accomplished by maintaining the fusion between the antibody fragment and portions of the filamentous bacteriophage coat protein 3, as present in the original antibody-displaying phage. In the present study, we have applied this system in an attempt to improve immunogenicity of anti-idiotypic antibodies isolated by phage display. Here we demonstrate that by preserving linkage between phage antibody and the N-terminal domain of phage coat protein 3, we induce multimerization of the antibody fragments, and improve their immunogenicity. This immunization approach allows induction of anti-idiotypic antibodies in mice, and facilitates the use of antibodies that are non-functional as non-fused soluble protein.
AB - Antibodies capable of recognizing key molecular targets isolated e.g. by phage display technology have been used in the pursuit of new and improved therapies for prevalent human diseases. These approaches often take advantage of non-immunogenic antibody fragments to achieve specific toxin-, radioactivity- or effector-domain delivery. There is now a growing interest in using anti-idiotypic antibodies or other antigen mimics to induce potent immune responses against antigen structures in question. We have earlier reported on the functional rescue of antibodies that are active when fused to the phage, but inactive as soluble protein [Jensen, K.B., Larsen, M., Pedersen, J.S., Christensen, P.A., Alvarez-Vallina, L., Goletz, S., Clark, B.F. and Kristensen, P. (2002) Functional improvement of antibody fragments using a novel phage coat protein III fusion system. Biochem. Biophys. Res. Commun. 298, 566-73.]. The rescue was accomplished by maintaining the fusion between the antibody fragment and portions of the filamentous bacteriophage coat protein 3, as present in the original antibody-displaying phage. In the present study, we have applied this system in an attempt to improve immunogenicity of anti-idiotypic antibodies isolated by phage display. Here we demonstrate that by preserving linkage between phage antibody and the N-terminal domain of phage coat protein 3, we induce multimerization of the antibody fragments, and improve their immunogenicity. This immunization approach allows induction of anti-idiotypic antibodies in mice, and facilitates the use of antibodies that are non-functional as non-fused soluble protein.
KW - Adjuvants, Immunologic/genetics
KW - Animals
KW - Antibodies, Anti-Idiotypic/immunology
KW - Antibodies, Monoclonal/genetics
KW - Capsid Proteins/genetics
KW - Female
KW - Humans
KW - Mice
KW - Mice, Inbred BALB C
KW - Recombinant Fusion Proteins/genetics
U2 - 10.1016/j.jim.2008.09.015
DO - 10.1016/j.jim.2008.09.015
M3 - Journal article
C2 - 18854189
SN - 0022-1759
VL - 339
SP - 220
EP - 227
JO - Journal of Immunological Methods
JF - Journal of Immunological Methods
IS - 2
ER -
